M.D. Anderson Cancer Center
This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT.
Primary Objective: To assess the overall survival of patients treated with standard of care systemic therapy with or without liver-directed hypofractionated adaptive RT. Secondary Objectives: * Patient-reported quality of life as per the FACT-Hep inventory * Progression-free survival * Cause of death
Inclusion Criteria: 1. Patients older than the age of 18 years old at the time of study entry. 2. Patients with a body mass greater than 30 kg. 3. Patients with a pathological diagnosis of intrahepatic cholangiocarcinoma and at least one intrahepatic tumor measuring 3 cm in greatest dimension 4. Patients must have pathological or radiographic evidence of either: c. locally advanced unresectable iCCA - a multidisciplinary discussion should be documented for patients who have liver confined disease, confirming that the patient is not resectable. d. extrahepatic metastasis at the time of…
Given by IV
Given by IV
Given by IV
Arctuva estimate
Verify or correct the compensation shown for this listing.